Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK [Phase 3]

View source ↗

Summary

Phase 3 DAYBREAK trial evaluating the efficacy and safety of two investigational agents (Tarcocimab Tedromer and Tabirafusp Tedromer) against aflibercept in wet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Tabirafusp Tedromer (Tabirafusp Tedromer)
• Tarcocimab Tedromer (Tarcocimab tedromer)

Snippet

Sponsor: Kodiak Sciences Inc | Conditions: Wet Age-related Macular Degeneration | Phase 3 | Status: ACTIVE_NOT_RECRUITING